RCT | Olaparib with or without Cediranib for metastatic castration-resistant prostate cancer.

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984 – Journal of Clinical Oncology

Commentary: Olaparib Plus Cediranib for mCRPC Lowers Radiographic Progression Risk – Renal & Urology News

Commentary on Twitter

Olaparib (#PARPi) combined with cediranib improved median radiographic PFS compared to olaparib alone in metastatic castrate-resistant #ProstateCancer ? https://t.co/guuQ0QQwfL #JCO #PCSM @Joseph_W_Kim pic.twitter.com/jr3GHHrndM

— Journal of Clinical Oncology (@JCO_ASCO) November 1, 2022